Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Neuropharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1519649
This article is part of the Research Topic Targeting Neuroinflammation for Novel Therapeutics in Neurodegenerative Diseases View all 14 articles

Enhanced Bioavailability of Quercetin-Loaded Niosomal In Situ Gel for the Management of Parkinson's Disease

Provisionally accepted
Abhishek A Revankar Abhishek A Revankar 1Archana S Patil Archana S Patil 1*Reshma Karishetti Reshma Karishetti 2Krutuja R Chougule Krutuja R Chougule 1Priyanka Patil Priyanka Patil 1Abhijit Salokhe Abhijit Salokhe 1
  • 1 KLE College of Pharmacy, Belgaum, Karnataka, India
  • 2 KLE University, Belgaum, Karnataka, India

The final, formatted version of the article will be published soon.

    Background: Parkinson's disease (PD) is the second most prevalent neurological disorder, characterized by motor symptoms such as tremor and rigidity due to the degeneration of dopaminergic neurons in the substantia nigra. This study investigates the formulation of quercetin, a natural bioflavonoid with potent antioxidant and anti-inflammatory properties, as niosomes for intranasal delivery to enhance its bioavailability and therapeutic potential for PD.The niosomal formulation was optimized for critical parameters including particle size, entrapment efficiency, and zeta potential. Male Wistar rats were utilized to assess the effects of quercetin-loaded niosomes on motor function, dopaminergic neuron protection, and oxidative stress alleviation.The optimized niosomal formulation exhibited a particle size of 195 nm, a polydispersity index (PDI) of 0.29, a zeta potential (ZP) of -30.63 mV, and an entrapment efficiency (EE) of 82.77%. In vivo evaluations conducted using the haloperidol-induced PD model revealed significant enhancements in behavioural, biochemical, and histopathological outcomes when compared to both disease controls and the standard treatment group.Additionally, short-term stability tests confirmed the robustness of the formulation.The findings suggest that the quercetin-loaded niosomal formulation offers improved drug delivery and efficacy, indicating its potential as a superior treatment option for PD compared to conventional dosage forms. This approach may pave the way for enhanced therapeutic strategies targeting the neurodegenerative processes underlying Parkinson's disease.

    Keywords: Biochemical assay, intranasal, Niosomes, Parkinson Disease, Quercetin

    Received: 30 Oct 2024; Accepted: 18 Dec 2024.

    Copyright: © 2024 Revankar, Patil, Karishetti, Chougule, Patil and Salokhe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Archana S Patil, KLE College of Pharmacy, Belgaum, 590010, Karnataka, India

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.